Good news is expected for people with food allergies

This is considered the most desirable food allergy treatment because peanut allergy is one of the top allergies today.

In the United States, an estimated 1.5 million children are allergic to peanuts. This allergy can become so severe that even people with this disease who are exposed to a small amount of peanuts can lead to very intense reactions.

In response to this, DBV Technologies, a French biotechnology company is currently studying a type of patch that can alleviate the severity of these allergies. This peanut allergy patch is currently taking part in the clinical trial process in three steps.

At the American Academy of Allergy, Asthma and Immunology Conference last Sunday, DBV Technologies showed that 83% of children between the ages of 6 and 11 participating in the trial could eat 1000 mg of peanuts without an allergic reaction after pasting this bandage for 3 years.

1000 mg of peanuts is 10 times the amount that participants can eat compared to when they started taking the test. Although the data show that the test participants are aged 6 to 55, the best test results come from children.

This patch can help people who are allergic to peanuts feel much more comfortable.

An allergy is the immune system's response to a certain substance but may not harm others. They are the sixth cause of chronic disease in the United States. According to CDC, an estimated 4% - 6% of American children are allergic to food and peanuts are one of the worst agents.

In December 2015, DBV started phase 3 testing to look at how stickers work in children between the ages of 4 and 11 and this data is also being submitted to the Food and Drug Administration by the company. US pharmaceuticals to apply for a license to widely use in the market.

How does this patch work?

Medications in patches affect the immune system distributed through the skin through a process called "immunotherapy with skin patches" (epicutaneous immunotherapy).

Inside each patch contains a sample of peanut protein solution. When you use this patch, proteins will find a way to get into your immune system through your skin. When transdermal in this way, allergens cannot enter the bloodstream and therefore an allergic reaction does not exist.

Based on data from the second trial phase of DBV, those who used this patch for three years at a dose of 250 micrograms (the highest dose) had the best responses to this method.

The patch treatment is derived from the way allergies are treated. Usually, the only way to reduce the negative reactions caused by allergies is to " desensitization ," the process of introducing a small amount of allergens into the body. . In the case of peanut allergies, it means helping your body absorb peanuts completely.

However, the problem is that this method is also very dangerous because it can cause a series of reactions because allergies spread throughout the body through the bloodstream. Other common methods focus on treating symptoms from an allergic reaction by using antihistamines such as Benadryl or Epinephrine in case of severe allergies.

In addition to peanut allergies, DBV is developing other types of patches to treat other food allergies like eggs and milk, one of the most common food allergies and non-food allergies. Relationship to asthma. The company also discovered treatments for Crohn's disease, celiac disease and type 1 diabetes with similar immune technology.